---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336716"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2026-08-06T11:10:16+00:00"
generated_at: "2026-08-06T11:15:37.710666+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q2 net income $22.7M; RGX-202 BLA on track; cash runway to Q4 2027

## Summary
- Net income of $22.7M ($0.43 per share) vs net loss of $70.9M in Q2 2025; revenue $108.0M (incl. $100M AbbVie milestone).
- RGX-202 Phase III AFFINITY DUCHENNE trial met primary endpoint (p<0.0001); BLA submission on track for Q3 2026 with potential accelerated approval 2H 2027.
- RGX-121 BLA resubmission on track for Q3 2026 after positive FDA Type A meeting; no additional studies required.
- Sura-vec (ABBV-RGX-314) pivotal wet AMD data expected Q4 2026; first patient dosed in NAAVIGATE DR study triggered $100M milestone.
- Pro forma cash ~$313M after July 2026 milestone and public offering; cash runway extended into Q4 2027.

## SEC filing metadata
- accession: 0001193125-26-336716
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2026-08-06T11:10:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/0001193125-26-336716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336716
- JSON: https://secwatch.observer/filing/0001193125-26-336716.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.